Drug Detail

Information about CGT9486

Generic Name
IND	CGT9486
Brand Name (US)
Manufacturer	Cogent Biosciences
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 2
Indications	Systemic mastocytosis, GIST
Overall Strategy	KIT and PDGFRA protein based
Strategy	Block KIT
Drug Category	KIT inhibitor

PLX9486 is designed to block KIT gene mutations. The drug was developed by Plexxicon and later acquired by Unum. The KIT mutations can cause cancer and cancer cell growth. By blocking these mutations, the drug may kill the cancer cells with the mutation and/or stop the tumor from growing. By combining PLX9486 with PLX3397, the investigators hope to block most gene mutations in KIT.
PLX9486 is also being developed for systemic mastocytosis. The key mutation in this disease occurs in KIT exon 17, D816V.